Skip to main content
Premium Trial:

Request an Annual Quote

Lentigen Licenses UPenn s Lentiviral Vector Tech for Reagent, Dx Development

NEW YORK, May 22 (GenomeWeb News) - Lentigen has received an exclusive worldwide license from the University of Pennsylvania to use its lentiviral vector technology, the company said today.

 

According to the company, the technology can be used to deliver genes or RNAi molecules into cells. The license gives Lentigen the right to use the technology to develop research reagents and therapeutics.

 

Financial terms of the arrangement were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.